Objective: To identify age-related changes in human meibomian glands that may be associated with meibomian gland dysfunction (MGD).
M
EIBOMIAN GLAND DYSfunction (MGD) is a common eyelid disorder that has widespread prevalence of 39% to 50% in the US population, 1 with the incidence increasing with age. [2] [3] [4] It is also a major cause of evaporative dry eye disease, with loss of glands resulting in decreased tear film lipid, unstable tear film, increased aqueous tear evaporation, 5 and increased tear film osmolarity, 6 leading to ocular surface changes and blepharitis. 7, 8 Currently, 3 forms of MGD are recognized: hypersecretory MGD, hyposecretory MGD, and obstructive MGD, with the latter form considered to be the most common. 9 Based on clinical and animal studies, [10] [11] [12] [13] [14] obstructive MGD is thought to involve hyperkeratinization of the meibomian gland duct, leading initially to plugging of the meibomian gland orifice followed by cystic dilation of the duct and a disuse atrophy of the acini that is detected as gland dropout on infrared photography (meibography). 9 While the risk of evaporative dry eye and MGD increases with age, 15, 16 there have been few histopathologic articles describing the effects of age on meibomian gland structure. 10, 17, 18 These reports suggest that aging results in atrophy of the meibomian gland acini and decreased lipid expression from the gland. 17, 18 Additional changes that have been noted include focal hyperkeratinization of the ductal epithelium, cystic dilation, and lipogranulomatoses, although the association with aging is less clear. 10 Recently, we identified specific age-related changes in the mouse meibomian gland that include decreased acinar cell proliferation, decreased meibomian gland size, and increased inflammatory cell infiltration that occur concurrently with altered localization of the peroxisome proliferator-activated receptor gamma (PPAR␥). 19 The PPAR␥ is a lipid-activated nuclear hormone receptor that regulates lipid synthesis and cell differentiation. 20 It has also recently been shown to be a marker for meibocyte differentiation in the developing mouse meibomian gland. 21 Because PPAR␥ is critical for sebocyte and adipocyte differentiation, 22 these findings suggest that age-related meibomian gland atrophy in the mouse may involve altered PPAR␥ signaling.
To assess whether age-related human MGD may involve similar changes to that identified in the mouse, we have evaluated human eyelid tissue taken from oculoplastic patients varying in age from 18 to 95 years. We report that human meibomian glands undergo similar agerelated changes to those identified in mice and therefore hypothesize that age-related human MGD may involve altered PPAR␥-regulated gene expression leading to downregulation of meibocyte differentiation, acinar atrophy, and hyposecretory MGD.
METHODS

HUMAN SUBJECT SELECTION AND ASSESSMENT
This study was conducted in accordance with the Declaration of Helsinki and was approved by the institutional review board at the University of California, Irvine, Medical Center. All subjects signed an informed consent form prior to enrollment in the study. Lower lateral eyelid specimens not affected by any disease processes were collected from subjects who underwent canthoplasty for treatment of various oculoplastic disorders (Table) . History of ocular and dermatological disorders was collected prior to surgery, and severity of MGD was evaluated in terms of gland expression and dropout. Meibomian gland expression was assessed in the region of the eyelid that was to be removed using a cotton-tipped applicator. Quality of expression was graded according to the degree of opacity and viscosity on a 0 to 4 scale based on Mathers et al 23 in which 0in-dicatesnormal; 1,opaque, normal viscosity; 2,opaque, increased viscosity; 3,severe thickening (toothpaste); and 4,no expression, glands completely blocked. Gland dropout was evaluated on a 0 to 4 scale along the entire lower eyelid: 0, none; 1,25%; 2,26% to 50%; 3,51% to 75%; and 4,76% to 100%.
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IMMUNOHISTOCHEMISTRY
Specimens were fixed in 2% paraformaldehyde in phosphate buffered saline (PBS, pH 7.4) overnight, then placed in 15% sucrose in PBS for 4 hours and transferred to 30% sucrose in PBS overnight. Lids were then embedded in Tissue-Tek OCT (optimal cutting temperature) (Sakura Finetek USA, Inc, Torrance, California) freezing medium, frozen in liquid nitrogen, and sectioned using a Leica CM1850 Cryotome (Leica, Wetzlar, Germany). Because samples varied in the amount of meibomian gland tissue, not all could be evaluated for every antibody.
Sections were first hydrated with PBS and then placed in freezing acetone (−20°C) for 3 minutes. Tissue sections were then blocked with 1% bovine serum albumin in PBS for 30 minutes at 37°C, and then incubated with primary antibodies including rabbit polyclonal anti-PPAR␥ (1:100; Abcam, Cambridge, Massachusetts), rabbit polyclonal anti-Ki67 (1:100; Abcam), and fluorescein isothiocyanate-conjugated antihuman common leukocyte antigen (CD45, clone HLe-1 [2D1], 1:100; R&D Systems, Minneapolis, Minnesota). Sections were then incubated for 1 hour at 37°C, washed with PBS, and reacted with fluorescein isothiocyanate-conjugated secondary antibodies against mouse, rabbit, or goat IgG (Invitrogen, Carlsbad, California) for 1 hour at 37°C. All samples were counterstained with 4',6-diamidino-2-phenylindole (DAPI) (300 nM) in PBS for 15 minutes. For negative controls, sections were either unstained, incubated with irrelevant IgG, or incubated with secondary antibodies alone. Sections were then evaluated and imaged using a Nikon Eclipse E600 fluorescence microscope (Nikon, Melville, New York).
MEASUREMENT OF KI67 LABELING INDEX
Digital images of anti-Ki67 stained sections from all specimens were analyzed using Metamorph Image analysis software (Molecular Devices, Downingtown, Pennsylvania) by an operator masked to the clinical diagnosis of the subject. Regions of the gland containing acini were first identified and the number of nuclei positively stained with anti-Ki67 antibodies marked and recorded using the cell count subroutine. The total number of nuclei within the basal cell layer was then counted using the same subroutine and the number recorded. Data were downloaded to an Excel spreadsheet (Microsoft, Redmond, Washington) and the labeling index calculated by dividing the number of Ki67-positive cell nuclei by the total number of acinar basal cells and multiplying by 100. All acini were counted in 3 different sections from each eyelid, and the average for each subject was recorded.
ANALYSIS OF LEUKOCYTE INFILTRATION
Digital images of sections stained with antibodies against CD45 were evaluated for the presence, localization, and degree of leukocyte infiltration. Each eyelid sample was assigned a − in the absence, ϩ in the presence of a few cells (1) (2) (3) (4) , and ϩϩ in the presence of high/marked (5 or more) cells infiltrating the acini and/or duct of the meibomian gland by CD45 positively stained cells.
STATISTICAL ANALYSIS
The relationship between age and other variables was determined using Sigma Stat (Systat Software, Inc, Point Richmond, California) stepwise linear regression analysis and calculation of Pearson correlation coefficient. P Ͻ .05 was considered statistically significant.
RESULTS
Specimens from 36 subjects were collected; the medical history and MGD grades for 2 subjects were not available with the tissue sample (Table) . The mean age was 75 years with a range of 18 to 95 years. There were 19 women (53%) and 17 men (47%). The surgical indications for the subjects are summarized in the Table. Of the 34 subjects with complete medical histories, 25 presented with rosacea (66.6%). Grading of MG expression identified 1 subject with normal secretions (2.9%), 4 exhibiting grade 1 secretions (11.8%) with opaque excretion but normal viscosity, 7 exhibiting grade 2 (20.6%) with opaque and increased viscosity, 16 (47.1%) exhibiting grade 3 with severe thickening, and 6 (17.6%) exhibiting grade 4 with no expression. There was a significant correlation between age and MG expression grade (r =0.749, PϽ .001), with older subjects displaying significantly higher grades (Table) .
All but 1 subject showed some degree of MG dropout, with 7 subjects (20.6%) having grade 1, 9 (26.5%) having grade 2, 12 (35.3%) having grade 3, and 5 (14.7%) having grade 4 MG dropout. Meibomian gland dropout was also significantly correlated with age (r = 0.618; PϽ .001). Moreover, MG dropout was highly correlated with MG expression grade (r =0.882; PϽ.001), indicating that higher MG expression grades showed significantly higher levels of MG dropout.
There was also a significant correlation between rosacea and MGD expression grade (r=0.419; P=.05), MG dropout (r=0.355; P=.05), and age (r=0.391; P=.05). However, when the 2 youngest subjects were removed from the study, the these correlations were no longer significant. It should be noted that the correlation between age and MGD expression grade or MG dropout remained significant after exclusion of the 2 youngest subjects.
MEIBOCYTE DIFFERENTIATION AND PROLIFERATIVE POTENTIAL
The PPAR␥ has been shown to be a marker for meibocyte differentiation in the developing mouse and shows a cytoplasmic/vesicular staining pattern in lipidproducing meibocytes in developing and adult glands that is lost in mice older than 1 year. 19, 21 The immunostaining of human eyelid tissue also showed 2 patterns in the localization of PPAR␥, cytoplasmic/vesicular and nuclear, that varied in proportion depending on sample age. Figure 1A shows the cytoplasmic and nuclear localization obtained for the 44-year-old meibomian gland. Note that this pattern was only observed in the 2 subjects younger than 50 years (18 and 44 years; Table) and is similar to that observed in young mice. 19 In contrast, Figure 1B shows predominantly nuclear localization of 
in all the samples from 58 to 95 years, with some showing cytoplasmic staining limited to the basal cell layer. When PPAR␥ staining was scored based on cytoplasmic staining for all acinar cells (ϩϩ), basal acinar cells (ϩ), or no cytoplasmic staining (−), there was a significant correlation with age (r= 0.664; P Ͻ.001), MGD expression grade (r = 0.484; P = .005), and MG dropout (r=0.401; P=.02). However, stepwise linear regression analysis showed that age was the only variable predictive of PPAR␥ staining (r 2 =0.441). Furthermore, the correlation between age and PPAR␥ remained significant when the 2 youngest subjects were excluded from the analysis.
To evaluate proliferative potential, we stained the samples with Ki67, a marker of cell cycle entry. There was a high labeling index for basal cells in the samples obtained from the subjects aged 44 and 18 years (Figure 2 ; Table) that was similar in magnitude to the labeling index reported for young mice. 19 Furthermore, samples from older subjects show substantially reduced labeling. Overall, there was a significant negative correlation between the Ki67 labeling index and age, with a correlation coefficient of −0.591, (r 2 =0.35; PϽ.001; Figure 3 ). However, the correlation was not significant if the youngest 2 subjects were excluded from the analysis.
LEUKOCYTE INFILTRATION
Immunofluorescent staining using antibodies to CD45 leukocyte marker showed variable amounts of CD45 ϩ leukocyte infiltration of the meibomian gland within the acinar, ductal, and interstitial regions of the gland (Figure 4) . Some samples showed positive CD45-stained cells in the ductal epithelium and interstitial tissue ( Figure 4 , A, B, and C), with no CD45-stained cells within the acini. Other samples showed CD45 ϩ cells within the acini but not the portion of the duct present in the section ( Figure 4D ). It was therefore not possible to ascertain whether any portion of the gland was preferentially infiltrated by CD45 ϩ cells. To assess the relationship between gland infiltration and MGD, the intensity of gland infiltration for each sample was noted as either negative (−), present (ϩ), or marked (ϩϩ). Because not all samples contained a section through the meibomian gland duct, analysis was limited to just the infiltration into the acini. Overall, CD45 leukocyte infiltration into the meibomian gland acini was significantly associated with the severity of MG expression grade (r = 0.414; P =.05), MG dropout (r = 0.361; P = .05), and patient age (r =0.341; P=.05). When the 2 youngest subjects were excluded from the analysis, the only correlation that remained significant was between acinar infiltration and MGD expression grade. The presence of rosacea showed no correlation with gland infiltration.
COMMENT
Given an asymmetric age distribution, the data from this study suggests that human meibomian glands show agerelated changes in acinar cell proliferation and localization of the lipogenesis factor, PPAR␥. These distinct agerelated changes are similar to those identified in aging mice that showed significant atrophy of meibomian glands in association with decreased acinar proliferation and altered PPAR␥ localization. 19 Additionally, meibomian glands exhibited variable amounts of leukocyte infiltration that are significantly correlated with the severity of MG expression grade but not with age. Taken together, the findings suggest that age-related MGD may involve altered PPAR␥ localization, suggesting altered regulation of PPAR␥ response genes that potentially lead to decreased meibocyte differentiation, acinar atrophy, decreased lipid synthesis, and the development of hyposecretory MGD.
However, it should be noted that these samples were obtained from subjects who underwent canthoplasty procedures for various underlying oculoplastic conditions and that tissue collection was limited to the lateral lower eyelid, which may introduce selection bias. In addition, there was an asymmetric age distribution with unequal sampling of younger subjects, which may also have biased these results. While the overall findings were consistent with findings in aging mice, evaluation of younger subjects is needed to substantiate these results. Verification of the of the relationship between meibomian gland atrophy and PPAR␥ localization using eyelid samples from cadaveric sources with a more complete age distribution would be helpful, although evaluating the relationship between clinical MGD and PPAR␥ localization, gland proliferation, and gland infiltration may be more difficult in these tissues.
The PPAR␥ is a fatty acid-activated nuclear transcription factor expressed predominantly in adipocytes and sebocytes, where it regulates the expression of genes involved in lipogenesis and is critical for appropriate cell differentiation to form fat and sebaceous glands. 22, 25 A diverse range of polyunsaturated fatty acids are thought to be the natural ligands for PPAR␥, including linoleic and linolenic acid, eicosapentaenoic acid, oxidized metabolites 9-and 13-hydroxyoctadecadienoic acid, 15-hydroxyeicosatetraenoic acid, and 15-deoxy-⌬ 12,14 -prostaglandin J2. 26 Synthetic ligands for PPAR␥, ie, thiazolidinediones, have been shown to have important anti-type 2 diabetic actions in controlling insulin resistance as well as beneficial effects on atherosclerosis and hypertension. 27 Binding of ligands to PPAR␥ result in heterodimerization with retinoic acid X receptors followed by binding to target gene promoters including aP2, a marker of terminal adipocyte differentiation, adiponectin, adipocyte differentiation-related protein, perilipin, and ace- tyl Co-A synthase. 27 The PPAR␥ can also serve as a molecular switch and recruit corepressors nuclear receptor corepressor and silencing mediator for retinoid and thyroid receptors when nonliganded PPAR␥ is bound to some target promoters. 28 There are also reports that PPAR␥ signaling may be modified by androgen receptors based on findings that androgen receptor-null mice show late-onset obesity with decreased PPAR␥ expression. 29 Distinct sex differences in the expression of PPAR␥ in some tissues have also been identified 30 as well as cell culture studies showing a synergistic activity between androgens and PPAR␥ ligands in immortalized sebocytes. 31 Finally, PPAR␥ activation is known to have pleiotropic effects on inflammatory cytokine expression in many organ systems. Recent studies have shown that activation of PPAR␥ by rosiglitazone, a thiazolidinediones class member, can reduce circulating interleukin 1 (IL-1) receptor antagonist when given to patients with metabolic syndrome while decreasing IL-1␤ and increasing IL-1Ra expression by THP-1 (human acute monocytic leukemia cell ine) monocytes in cultures. 32 Similar effects have been shown for synovial fibroblasts treated with rosiglitazone. 33 Furthermore, successful treatment of inflammatory bowel disease, psoriasis, and obstructive pulmonary disease and the downregulation of proinflammatory mediators associated with these chronic diseases have also been reported for synthetic PPAR␥ agonist. 34 Together, the reported actions of PPAR␥ appear to be relevant to many of the known ocular surface changes involved in age-related MGD. First, androgens have been shown to effect meibomian gland gene expression, [35] [36] [37] [38] and women with androgen insensitivity show altered meibomian gland lipid profiles that might act through downstream PPAR␥ gene regulation. [39] [40] [41] Second, some improvement in dry eye disease has been reported using dietary supplements containing omega 3 and omega 6 fatty acids, 42 the natural ligands for PPAR␥. Third, ocular surface disease has been shown to be associated with upregulation of proinflammatory cytokines such as IL-1 and tumor necrosis factor ␣, [43] [44] [45] the expression of which has been reported to be modulated by PPAR␥ during chronic disease. [32] [33] [34] Finally, Accutane therapy, which acts through retinoic acid Xreceptor binding, the heterodimeric partner of PPAR␥, is known to cause dry eye disease and hyposecretory MGD. [46] [47] [48] While it is not known if PPAR␥ influences these ocular surface disease pathways, future studies are clearly needed to identify the role of PPAR␥ in regulating meibomian gland function and it's influence on the development of MGD.
Overall, the findings in this study suggest that agerelated MGD may be associated with hyposecretory MGD that differs from the accepted obstructive MGD mechanism ( Figure 5) . 9, 49 In obstructive MGD, hyperkeratinization of the meibomian gland orifice is thought to lead to cystic ductal dilation and downstream disuse atrophy of the meibomian gland acini. This hypothesis is based on findings in animal models showing that chemically induced gland hyperkeratinization leads to initial blockage of the orifice. 11, 12, 14 A few histopathologic studies have also described regional hyperkeratinization in human glands. 10, 18 However, it should be noted that a hallmark of MGD in subjects is gland dropout, as seen clinically by slitlamp examination and infrared meibography. 23, 50 By comparison, hyperkeratinized animal eyelids show swelling of the gland and increased transillumination defects starting at the gland orifice. 11, 13 In age-related MGD, we hypothesize that meibomian gland aging leads to altered PPAR␥ response gene regulation that directly effects meibocyte differentiation, resulting in acinar atrophy, gland dropout, and a hyposecretory MGD. This mechanism is consistent with our finding that MG dropout significantly correlates with age and MG expression grade, which has been shown to correlate with increased ocular surface water evaporation. 15, 16, 51 Importantly, this mechanism suggests that the quantity, not the quality, of the meibomian gland secretions may play an initial role in the development of agerelated MGD and evaporative dry eye that may occur alone or in conjunction with obstructive MGD. It also suggests that the inflammatory changes that develop during evaporative dry eye may be secondary downstream changes, as indicated by the stronger correlation between acinar infiltration and MGD expression grade in favor of age and MG dropout. This stronger association may also be explained by the pleiotropic effects of PPAR␥ on cytokine expression within the gland. 34 Clearly, additional study into the role of PPAR␥ in regulating meibomian gland function may provide important insights into the mechanism underlying age-related MGD as well as suggest novel therapeutic approaches to the treatment of evaporative dry eye. 
